adalimumab (preferred products) — Highmark
Ankylosing Spondylitis (AS)
Initial criteria
- age ≥ 18 years
- diagnosis of AS
- prescribed by or in consultation with a rheumatologist
Reauthorization criteria
- member has demonstrated disease stability or a beneficial response to therapy